Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics-Reference-Cited by-同舟云学术

Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

Published:2017-05-30 Issue:19 Volume:123 Page:3843-3854
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ocean Allyson J.¹,Starodub Alexander N.²,Bardia Aditya³,Vahdat Linda T.¹,Isakoff Steven J.³,Guarino Michael⁴,Messersmith Wells A.⁵,Picozzi Vincent J.⁶,Mayer Ingrid A.⁷,Wegener William A.⁸,Maliakal Pius⁸,Govindan Serengulam V.⁸,Sharkey Robert M.⁸^ORCID,Goldenberg David M.⁸

Affiliation:

1. Weill Cornell Medicine; New York New York

2. Indiana University Health Center for Cancer Care; Goshen Indiana

3. Massachusetts General Hospital Cancer Center, Harvard Medical School; Boston Massachusetts

4. Helen F. Graham Cancer Center; Newark Delaware

5. University of Colorado Cancer Center; Aurora Colorado

6. Virginia Mason Cancer Center; Seattle Washington

7. Vanderbilt-Ingram Cancer Center; Nashville Tennessee

8. Immunomedics, Inc; Morris Plains New Jersey

Funder

Immunomedics, Inc.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference36 articles.

1. New developments for antibody-drug conjugate-based therapeutic approaches;Goeij;Curr Opin Immunol,2016

2. The European Medicines Agency review of brentuximab vedotin (Adcetris) for the treatment of adult patients with relapsed or refractory CD30 + Hodgkin lymphoma or systemic anaplastic large cell lymphoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use;Gravanis;Oncologist,2016

3. Antibody-drug conjugates: a clinical pharmacy perspective on an emerging cancer therapy;Jerjian;Pharmacotherapy,2016

4. Prospects and progress of antibody-drug conjugates in solid tumor therapies;Govindan;Expert Opin Biol Ther,2016

5. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins;Garcia-Carbonero;Clin Cancer Res,2002

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01;Journal of Clinical Oncology;2024-09-12

2. On the shoulder of ADC: The development of 124I-IMMU-132, an iodine-124-labelled Trop-2-targeting molecular probe for micro-PET imaging;Biomedicine & Pharmacotherapy;2024-09

3. Trop2-targeted therapy in breast cancer;Biomarker Research;2024-08-13

4. Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial;Nature Communications;2024-08-07

5. Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer;Gynecologic Oncology Reports;2024-08